Chronic Prostatitis
Conditions
Keywords
interferon gamma, IFN-g, Chronic prostatitis
Brief summary
The primary purposes of the study are to evaluate the effectiveness of Ingaron in the complex therapy of chronic prostatitis, to assess the safety of using Ingaron in patients with chronic prostatitis.
Detailed description
Literature data and the results of preclinical studies of interferon-gamma, as well as the features of the immunopathogenesis of chronic prostatitis, show the expediency of studying the use of Ingaron in this pathology. The study was conducted to compare the efficacy and safety of Ingaron in combination with standard therapy with its subcutaneous administration and standard therapy in patients with chronic prostatitis. The study was planned to include 50 male patients aged at least 18 years with a confirmed diagnosis of chronic prostatitis. In the course of the study, Ingaron was administered at a dose of 500,000 IU once a day, every other day. In addition to Ingaron, patients received antibiotic therapy, anti-inflammatory drugs, alpha-blockers (if necessary). Magnetic laser therapy and prostate massage were also provided. The patients were divided into 2 groups: main and control.
Interventions
received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Sponsors
SPP Pharmaclon Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age at least 18 years old (at the time of inclusion). 2. Objectively confirmed diagnosis of chronic prostatitis at the time of inclusion in the study (more than 10 leukocytes / field of view in cytological examination of prostate secretion; more than 1x10\^5 CFU in bacteriological examination of prostate secretion (regardless of the nature of the inoculated microflora)). 3. Concomitant myco-, ureaplasma, gardnerella, chlamydial, urogenital viral infection is not excluded. 4. The volume of residual urine (Q max) is not more than 70 ml. 5. The maximum urination rate, according to urofluometry, is not less than 10 ml / sec. 6. Allowed previous therapy of chronic prostatitis, not less than 30 days after the end of the last course of treatment. 7. If there is a history of surgical treatment for benign prostatic hyperplasia, the time from the moment of surgery to inclusion in the study is at least 6 months. 8. Availability of written informed consent to participate in the clinical study.
Exclusion criteria
1. Positive test results for syphilis (Wasserman reaction), hepatitis (HbsAg, anti-HCV), HIV infection. 2. Known allergic reactions to interferons, or other significant allergic diseases. 3. A history of autoimmune disease. 4. The presence of external drains of the organs of the genitourinary system. 5. The presence of histologically proven prostate cancer. 6. A history of diabetes mellitus. 7. Any immunotropic therapy within the last 6 weeks prior to enrollment in the study. 8. Condition after organ transplantation, constant intake of immunosuppressive drugs. 9. Severe pathology from the cardiovascular system (uncontrolled arterial hypertension, unstable angina pectoris, congestive heart failure, cardiac arrhythmias), a history of myocardial infarction or cerebrovascular accident within the last 6 months. 10. Severe pathology of the liver (increased content of AST, ALT 2 times higher than the upper limit of the norm, the content of total bilirubin\> 2 mg / dl), kidney (creatinine content\> 1.5 mg / dl); signs of hepatic and / or renal failure. 11. Other serious (acute or chronic) pathological conditions, including mental illness, as well as abnormalities in laboratory parameters, which, in the opinion of the investigator, may increase the risk associated with participation in the study or affect the interpretation of the efficacy and safety data obtained in this research. 12. Alcohol and / or drug dependence. 13. Participation in other clinical trials in the last 3 months prior to inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dynamics of the total score and improvement in the quality of life on the scale IPSS. | Day 13 | The sum of points was assessed, as well as the symptom complex on the basis of the IPSS questionnaire - the international system for the total assessment of symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms was assessed from 0 to 6 points. symptoms of prostate diseases in points (WHO, 1992). The severity of symptoms is rated from 0 to 6 points. |
| Immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 14 | Content of polymorphonuclear leukocytes in prostate secretion. |
| Evaluation of cytological parameters of prostate secretion. | Day 14 | The number of lecithin grains. |
| Microscopy of prostate secretion and immunohistochemical study of prostate secretion with assessment of cytological parameters. | Day 14 | The effect of interferon-gamma on T-lymphocytes. |
| Evaluation of indicators of urination. Ultrasound of the prostate gland. | Day 90 | Ultrasound of the prostate gland. |
| Evaluation of indicators of urination. Urofluometry. | Day 90 | Urofluometry. |
| Evaluation of indicators of urination. General urine analysis. | Day 90 | General urine analysis. |
| Evaluation of the inter-relapse period. Identification of an exacerbation of a chronic process. | Month 3 | Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period. |
| Evaluation of the inter-relapse period. Identification of signs of a relapse of the disease. | Month 3 | Percentage of patients with exacerbation of chronic prostatitis and signs of disease recurrence during the follow-up period. |
Outcome results
None listed